Cargando…
Preoperative serum HER2 extracellular domain levels in primary invasive breast cancer
BACKGROUND: Despite the preclinical outcomes and biologic significance of the presence of the human epidermal growth factor receptor-2 (HER2) extracellular domain (ECD), there is little evidence supporting the measurement of ECD levels in any clinical setting. The aim of this study was to determine...
Autores principales: | Lee, Sae Byul, Lee, Jong Won, Yu, Jong Han, Ko, Beom Seok, Kim, Hee Jeong, Son, Byung Ho, Gong, Gyungyub, Lee, Hee Jin, Kim, Sung-Bae, Jung, Kyung Hae, Ahn, Jin-Hee, Lee, Woochang, Sung, Joohon, Ahn, Sei-Hyun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4295268/ https://www.ncbi.nlm.nih.gov/pubmed/25491647 http://dx.doi.org/10.1186/1471-2407-14-929 |
Ejemplares similares
-
Plasma Proteome Signature to Predict the Outcome of Breast Cancer Patients Receiving Neoadjuvant Chemotherapy
por: Gwark, Sungchan, et al.
Publicado: (2021) -
Metformin increases survival in hormone receptor-positive, HER2-positive breast cancer patients with diabetes
por: Kim, Hee Jeong, et al.
Publicado: (2015) -
Usefulness of 3D-surgical guides in breast conserving surgery after neoadjuvant treatment
por: Lee, Han Shin, et al.
Publicado: (2021) -
Survival Outcome of Combined GnRH Agonist and Tamoxifen Is Comparable to That of Sequential Adriamycin and Cyclophosphamide Chemotherapy Plus Tamoxifen in Premenopausal Patients with Lymph-Node–Negative, Hormone-Responsive, HER2-Negative, T1-T2 Breast Cancer
por: Sohn, Guiyun, et al.
Publicado: (2016) -
Change in Estradiol Levels among Premenopausal Patients with Breast Cancer Treated Using Leuprolide Acetate 11.25 Milligrams 3-Month Depot and Tamoxifen
por: Lee, Young-jin, et al.
Publicado: (2020)